Evidence map›Paper›PMID 28440817›Full record

ArticleTranslational psychiatry2017

Effects of dopamine D2/D3 receptor antagonism on human planning and spatial working memory.

M Naef, U Müller, A Linssen, L Clark, T W Robbins, C Eisenegger

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 34 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Dopamine D2 Receptor Modulates Exercise Related Effect on Cortical Excitation/Inhibition and Motor Skill Acquisition.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2024
    Trial
  5. Pramipexole modulates fronto-subthalamic pathway in sequential working memory.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023
    Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 4 countries.

M NaefDepartment of Economics, Royal Holloway, University of London, Egham, UK.
U MüllerBehavioural and Clinical Neuroscience Institute, Department of Psychology, University of Cambridge, Cambridge, UK.
A LinssenDepartment of Neuropsychology and Psychopharmacology, Maastricht University, Maastricht, The Netherlands.
L ClarkBehavioural and Clinical Neuroscience Institute, Department of Psychology, University of Cambridge, Cambridge, UK.
T W RobbinsBehavioural and Clinical Neuroscience Institute, Department of Psychology, University of Cambridge, Cambridge, UK.
C EiseneggerNeuropsychopharmacology and Biopsychology Unit, Department of Basic Psychological Research and Research Methods, Faculty of Psychology, University of Vienna, Vienna, Austria.
University of Cambridge · GBMaastricht University · NLRoyal Holloway University of London · GBUniversity of British Columbia · CAUniversity of Vienna · AT

Funding

Medical Research Council G0001354Medical Research Council G1000183Wellcome Trust
6 · The paper itself

Abstract

Psychopharmacological studies in humans suggest important roles for dopamine (DA) D2 receptors in human executive functions, such as cognitive planning and spatial working memory (SWM). However, studies that investigate an impairment of such functions using the selective DA D2/3 receptor antagonist sulpiride have yielded inconsistent results, perhaps because relatively low doses were used. We believe we report for the first time, the effects of a higher (800 mg p.o.) single dose of sulpiride as well as of genetic variation in the DA receptor D2 gene (DA receptor D2 Taq1A polymorphism), on planning and working memory. With 78 healthy male volunteers, we apply a between-groups, placebo-controlled design. We measure outcomes in the difficult versions of the Cambridge Neuropsychological Test Automated Battery One-Touch Stockings of Cambridge and the self-ordered SWM task. Volunteers in the sulpiride group showed significant impairments in planning accuracy and, for the more difficult problems, in SWM. Sulpiride administration speeded response latencies in the planning task on the most difficult problems. Volunteers with at least one copy of the minor allele (A1+) of the DA receptor D2 Taq1A polymorphism showed better SWM capacity, regardless of whether they received sulpiride or placebo. There were no effects on blood pressure, heart rate or subjective sedation. In sum, a higher single dose of sulpiride impairs SWM and executive planning functions, in a manner independent of the DA receptor D2 Taq1A polymorphism.

Indexed as

AdultCognitionDopamine AntagonistsDopamine D2 Receptor AntagonistsDouble-Blind MethodHumansMalePolymorphism, GeneticPsychopharmacologyReaction TimeReceptors, Dopamine D2Receptors, Dopamine D3Spatial MemorySulpirideDopamine AntagonistsDopamine D2 Receptor AntagonistsDRD2 protein, humanReceptors, Dopamine D2Receptors, Dopamine D3Sulpiride

Identifiers

PMID28440817
PMCPMC5416697
OpenAlexW2607366508

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.